Vivo Capital LLC Sells 205,571 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

Vivo Capital LLC decreased its position in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 11.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,650,440 shares of the company’s stock after selling 205,571 shares during the period. Sera Prognostics makes up 0.8% of Vivo Capital LLC’s holdings, making the stock its 26th biggest position. Vivo Capital LLC owned 5.27% of Sera Prognostics worth $9,870,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. CWM LLC acquired a new stake in shares of Sera Prognostics during the 4th quarter worth $242,000. Resource Consulting Group Inc. acquired a new stake in shares of Sera Prognostics during the fourth quarter valued at about $265,000. Vanderbilt University acquired a new stake in shares of Sera Prognostics during the fourth quarter valued at about $284,000. Finally, Perigon Wealth Management LLC bought a new position in shares of Sera Prognostics during the fourth quarter worth about $509,000. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Stock Performance

Shares of SERA traded up $0.24 during mid-day trading on Thursday, reaching $9.54. 5,462 shares of the company were exchanged, compared to its average volume of 212,575. The stock has a market capitalization of $309.38 million, a PE ratio of -8.02 and a beta of 1.33. The business has a 50 day simple moving average of $9.67 and a two-hundred day simple moving average of $6.69. Sera Prognostics, Inc. has a 52 week low of $1.52 and a 52 week high of $12.35.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, March 20th. The company reported ($0.25) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.25). Sera Prognostics had a negative return on equity of 45.74% and a negative net margin of 11,843.79%. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.10 million. On average, analysts predict that Sera Prognostics, Inc. will post -0.94 EPS for the current year.

Insider Buying and Selling at Sera Prognostics

In other Sera Prognostics news, CFO Austin Aerts sold 8,092 shares of the firm’s stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $9.37, for a total value of $75,822.04. Following the completion of the sale, the chief financial officer now owns 322,488 shares of the company’s stock, valued at $3,021,712.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider John J. Boniface sold 21,438 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $9.55, for a total transaction of $204,732.90. Following the transaction, the insider now owns 143,524 shares of the company’s stock, valued at $1,370,654.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Austin Aerts sold 8,092 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $9.37, for a total value of $75,822.04. Following the transaction, the chief financial officer now directly owns 322,488 shares in the company, valued at approximately $3,021,712.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 92,903 shares of company stock valued at $866,284. Company insiders own 15.80% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.